Lung Disease Cough Therapy Update to Be Reviewed
Adults with lung disease-linked chronic cough can follow the company's investigational treatment progress on November 9.
Updated on Nov. 2, 2026 in Asthma

Trevi Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call and webcast on November 9, 2026, at 4:30 p.m. ET to review its financial results for the quarter ended September 30, 2026. The company is developing Haduvio (oral nalbuphine ER) for chronic cough, a condition that affects patients with idiopathic pulmonary fibrosis and other interstitial lung diseases.
Why it matters
Chronic cough linked to lung disease has few treatment options, and the company's update on its investigational therapy will show how development is progressing for patients with limited choices. The FDA has conditionally accepted Haduvio as the trade name for nalbuphine ER, a regulatory step that signals the program is moving forward.
Trevi reports that Haduvio produced a statistically significant reduction in cough frequency in clinical trials, though the stub does not specify trial design, sample size, or effect magnitude. No FDA-approved therapies currently exist for chronic cough in IPF and non-IPF interstitial lung disease, underscoring the unmet need the company is targeting.
The players
Trevi Therapeutics
A clinical-stage biopharmaceutical company based in New Haven, Connecticut, developing Haduvio for chronic cough associated with lung disease.
The details
Haduvio is an oral, extended-release form of nalbuphine, a compound the company is studying for chronic cough in three groups: patients with idiopathic pulmonary fibrosis, patients with non-IPF interstitial lung disease, and patients with refractory chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Administration, which the company's materials note in the context of its development. Chronic cough in these conditions can be severe, with some patients coughing as many as 1,500 times per day, which the company cites as the burden its therapy aims to address.
Timeline
November 9, 2026: Conference call and webcast reviewing Q3 2026 results begin at 4:30 p.m. ET.
September 30, 2026: End of the quarter being reported in the upcoming call.
30 days after the event: Archived webcast replay remains available on the company's website.
Health Landscape
Chronic cough in interstitial lung disease has long lacked an FDA-approved treatment, leaving clinicians with limited tools for a symptom that can dominate patients' lives. Trevi's Haduvio program sits among the investigational efforts aimed at filling that gap across IPF, non-IPF ILD, and refractory chronic cough.
If you live with chronic cough linked to lung disease, this update signals ongoing development of new treatment options, and it is worth raising persistent cough with your physician. Those with a diagnosis of IPF or interstitial lung disease can discuss current symptom management and clinical trial options with their care team.
The takeaway
Chronic cough in lung disease remains a major unmet need, with no FDA-approved therapies yet available for these patients. Anyone tracking treatment progress for interstitial lung disease can follow the company's November 9 update and discuss persistent cough with a physician.
What happens next
Trevi Therapeutics will host its conference call and webcast on November 9, 2026, at 4:30 p.m. ET, where it is expected to review its quarterly results.
Further reading
Explore more coverage of Asthma and related lung conditions in our health section.
More information
Register for the Trevi investor event through the company's investor relations site.
Source note: This article includes information reported by The Manila times.





